Tech Company Financing Transactions
Yumanity Funding Round
Yumanity, operating out of Cambridge, secured $45 million from Fidelity Management & Research Company, Alexandria Venture Investments and Biogen Idec.
Transaction Overview
Company Name
Announced On
2/11/2016
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A financing will accelerate efforts to advance Yumanity Therapeutics' proprietary platforms aimed at identifying novel therapies to treat neurodegenerative diseases caused by protein misfolding including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
790 Memorial Dr. 2C
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Yumanity Therapeutics is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tony Coles
Chief Scientific Officer
Kenneth Rhodes
Vice President
Robert Scannevin
VP - Bus. Development
Paulash Mohsen
VP - Product Management
Bertrand Bourdonnec
Browse more venture capital transactions:
Prev: 2/11/2016: Waterline Data venture capital transaction
Next: 2/11/2016: scriptr.io venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs